Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$12.27
+1.5%
$9.08
$5.51
$12.48
$1.59B1.232.79 million shs2.26 million shs
Biohaven Ltd. stock logo
BHVN
Biohaven
$15.70
+10.3%
$14.50
$12.79
$55.70
$1.51B0.982.04 million shs2.81 million shs
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
$25.11
+0.6%
$24.61
$21.97
$71.71
$1.50B2.86895,949 shs527,337 shs
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
$14.72
+11.4%
$12.21
$4.81
$27.50
$494.50MN/A329,571 shs577,730 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
+1.49%+7.92%+38.64%+49.82%+119.50%
Biohaven Ltd. stock logo
BHVN
Biohaven
+10.56%+6.65%+17.57%-2.30%-58.79%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
+0.56%+9.99%-7.00%+3.42%-37.49%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
+11.43%+21.05%+18.42%+31.90%+1,471,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
2.8348 of 5 stars
1.53.00.00.02.92.53.1
Biohaven Ltd. stock logo
BHVN
Biohaven
3.7968 of 5 stars
4.53.00.00.02.82.50.6
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
2.3871 of 5 stars
3.53.00.00.02.31.70.0
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
2.577 of 5 stars
3.50.00.00.03.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
3.00
Buy$12.00-2.20% Downside
Biohaven Ltd. stock logo
BHVN
Biohaven
3.07
Buy$53.75242.36% Upside
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
3.08
Buy$91.89265.95% Upside
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
3.00
Buy$37.75156.45% Upside

Current Analyst Ratings Breakdown

Latest MBX, BHVN, AUPH, and JANX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/15/2025
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Buy$36.00
8/12/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$54.00 ➝ $30.00
8/12/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$60.00 ➝ $50.00
8/12/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$63.00 ➝ $54.00
8/12/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$57.00 ➝ $52.00
8/12/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$50.00 ➝ $49.00
8/5/2025
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$38.00
8/1/2025
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$8.00 ➝ $9.00
7/30/2025
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$17.00
7/16/2025
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$38.00
7/11/2025
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$65.00
(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$260.11M6.21$0.31 per share39.20$2.55 per share4.81
Biohaven Ltd. stock logo
BHVN
Biohaven
N/AN/AN/AN/A$1.27 per shareN/A
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
$10.59M142.48N/AN/A$16.48 per share1.52
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$5.75M$0.4328.5421.91N/A23.31%20.06%13.81%N/A
Biohaven Ltd. stock logo
BHVN
Biohaven
-$846.42M-$7.66N/AN/AN/AN/A-270.65%-143.70%N/A
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-$68.99M-$1.80N/AN/AN/AN/A-11.48%-11.01%N/A
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/A-$4.54N/AN/AN/AN/AN/AN/AN/A

Latest MBX, BHVN, AUPH, and JANX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q1 2025
Biohaven Ltd. stock logo
BHVN
Biohaven
-$1.94-$1.94N/A-$1.94$0.41 millionN/A
8/7/2025Q2 2025
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-$0.48-$0.55-$0.07-$0.55$0.30 millionN/A
7/31/2025Q2 2025
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$0.17$0.16-$0.01$0.16$64.27 million$70.01 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/A
Biohaven Ltd. stock logo
BHVN
Biohaven
N/AN/AN/AN/AN/A
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
N/AN/AN/AN/AN/A
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
0.18
5.23
4.63
Biohaven Ltd. stock logo
BHVN
Biohaven
1.91
3.82
2.33
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
N/A
47.03
47.03
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
36.83%
Biohaven Ltd. stock logo
BHVN
Biohaven
88.78%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
75.39%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/A

Insider Ownership

CompanyInsider Ownership
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
12.20%
Biohaven Ltd. stock logo
BHVN
Biohaven
16.00%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
8.10%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
52.19%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
300131.63 million115.57 millionOptionable
Biohaven Ltd. stock logo
BHVN
Biohaven
239105.79 million88.86 millionOptionable
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
3060.09 million55.23 millionOptionable
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
3633.59 millionN/AN/A

Recent News About These Companies

A Glimpse of MBX Biosciences's Earnings Potential
MBX Biosciences Inc Executives - Morningstar
MBX Biosciences Inc Chart - Morningstar

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurinia Pharmaceuticals stock logo

Aurinia Pharmaceuticals NASDAQ:AUPH

$12.27 +0.18 (+1.49%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$12.36 +0.10 (+0.77%)
As of 08/15/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Biohaven stock logo

Biohaven NYSE:BHVN

$15.70 +1.47 (+10.33%)
Closing price 08/15/2025 03:58 PM Eastern
Extended Trading
$15.55 -0.15 (-0.96%)
As of 08/15/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Janux Therapeutics stock logo

Janux Therapeutics NASDAQ:JANX

$25.11 +0.14 (+0.56%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$25.12 +0.02 (+0.06%)
As of 08/15/2025 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

MBX Biosciences stock logo

MBX Biosciences NYSE:MBX

$14.72 +1.51 (+11.43%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$14.50 -0.23 (-1.53%)
As of 08/15/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.